GlassScriptPhysician profile
Nitin K Gupta
NPI 1457647646
$34,684.10
in general payments reported to CMS, 2019-2025
48 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,150 · 2020: $6,479 · 2021: $6,572 · 2022: $1,280 · 2023: $2,613 · 2024: $16K · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,631 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,450 · Education: $4,518 · Travel and Lodging: $3,569 · Gift: $34.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,631.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,450.00 |
| Education | $4,518.00 |
| Travel and Lodging | $3,568.92 |
| Gift | $34.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11,543.01 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Intuitive Surgical, INC. | $10,170.62 | 2023-2024 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $7,973.73 | 2019-2025 | Tagrisso, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,136.05 | 2019-2023 | Ofev |
| Genzyme Corporation | $416.11 | 2020-2024 | |
| Mylan Specialty L.P. | $385.46 | 2020-2023 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $316.28 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $302.62 | 2019-2025 | Prolastin-C Liquid |
| Abiomed | $269.82 | 2019-2023 | Impella |
| Takeda Pharmaceuticals U.S.A., INC. | $165.37 | 2021-2025 | Glassia |
| Abbott Laboratories | $161.03 | 2024 | Esprit |
| Alexion Pharmaceuticals, INC. | $136.28 | 2019-2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $128.78 | 2019-2023 | |
| Optinose US, INC. | $111.10 | 2019-2021 | |
| Pulmonx Corporation | $106.48 | 2023-2024 | Zephyr Delivery Catheter, Chartis Catheter, Zephyr Endobronchial Valve |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.